Compare · CTOR vs NVO
CTOR vs NVO
Side-by-side comparison of Citius Oncology Inc. (CTOR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTOR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $188.51B, about 2427.0x CTOR ($77.7M).
- Over the past year, CTOR is up 1.4% and NVO is down 35.7% - CTOR leads by 37.1 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 3 for CTOR).
- NVO has more recent analyst coverage (25 ratings vs 2 for CTOR).
- Company
- Citius Oncology Inc.
- Novo Nordisk A/S
- Price
- $0.89+2.53%
- $42.20+4.75%
- Market cap
- $77.7M
- $188.51B
- 1M return
- +78.18%
- +14.85%
- 1Y return
- +1.35%
- -35.72%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 3
- 6
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTOR
- Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Citius Oncology Ships First International Order of LYMPHIR™ to Europe
- Citius Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
- Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
- Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
- SEC Form EFFECT filed by Citius Oncology Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S